Nifty Pharma News and Updates

Name: Latest research reports of Divi's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Divi's Laboratories Ltd.

29 Aug 2025

6131.50

-0.01%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6112.1

Cipla Ltd.

27 Aug 2025

1589.40

0.58%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025

Dr. Reddy's Laboratories Ltd.

26 Aug 2025

1260.10

0.02%

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Business Standard

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr Reddy's launches drug for treatment of chronic constipation

Business Line | 26 Aug 2025 1 more

Aurobindo Pharma Ltd.

26 Aug 2025

1027.90

0.16%

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

Business Standard

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Aurobindo Pharma Ltd. has lost -34.50% in the last 1 Year

Sun Pharmaceutical Industries Ltd.

26 Aug 2025

1594.50

0.55%

Sun Pharma shares slip 3% after BofA downgrade on premium valuations

Economic Times

Bank of America downgraded Sun Pharma stock to underperform' from neutral', citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Zydus Lifesciences Ltd.

25 Aug 2025

981.05

0.25%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.

Zydus Lifesciences L.. has an average target of 1021.00 from 6 brokers.

Cipla Ltd.

22 Aug 2025

1589.40

0.58%

Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And OthersCheck Target Price

NDTV Profit

The stock recommendations come with specific target price and stop loss price.

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Cipla Ltd.

22 Aug 2025

1589.40

0.58%

Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla

Business Standard

Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Granules India Ltd.

22 Aug 2025

492.25

5.35%

Can Granules India leverage its strong product pipeline to offset recent profit declines?

Economic Times

Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.

Granules India Ltd. is trading below its 150 day SMA of 495.2

Granules India Ltd.

22 Aug 2025

492.25

5.35%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Granules India Ltd. is trading at high volume of 16.9M with price gain of 5.35.

Is Nifty Pharma worth buying?

322 Votes:

Buy 79.19%

Sell 11.8%

Hold 9.01%

Nifty Pharma PB	4.7
Nifty Pharma PE	31.6
Nifty Pharma DIV	0.7
Nifty Pharma EPS	689.4

Nifty Pharma PB

Nifty Pharma PE

Nifty Pharma DIV

Nifty Pharma EPS

Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.